These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 23417624)

  • 1. New preventive strategy to eliminate measles, mumps and rubella from Europe based on the serological assessment of herd immunity levels in the population.
    Plans P
    Eur J Clin Microbiol Infect Dis; 2013 Jul; 32(7):961-6. PubMed ID: 23417624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is the current prevention strategy based on vaccination coverage and epidemiological surveillance sufficient to achieve measles and rubella elimination in Europe?
    Plans-Rubio P
    Expert Rev Anti Infect Ther; 2014 Jul; 12(7):723-6. PubMed ID: 24807016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the measles, mumps and rubella immunisation programme in Spain by using a sero-epidemiological survey.
    Amela C; Pachón I; de Ory F
    Eur J Epidemiol; 2003; 18(1):71-9. PubMed ID: 12705626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of immune status against measles, mumps, and rubella in young Kuwaitis: MMR vaccine efficacy.
    Madi N; Altawalah H; Alfouzan W; Al-Nakib W; Al-Roumi E; Jeragh A
    J Med Virol; 2020 Aug; 92(8):963-970. PubMed ID: 31919861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Morbidity, vaccine coverage and immunity against measles, mumps and rubella in a Gallician population from 2 to 5 years old].
    Vázquez Fernández E; López Rois F; Vázquez Carrete JA; Gómez Tato B; Alvarez Ares M
    An Esp Pediatr; 1987 Jul; 27(1):27-31. PubMed ID: 3662251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measles, Mumps, and Rubella Serostatus and Response to MMR Vaccination Among HIV-Infected Adults.
    Singh HK; Chiu YL; Wilkin T
    AIDS Patient Care STDS; 2015 Sep; 29(9):461-4. PubMed ID: 26153909
    [No Abstract]   [Full Text] [Related]  

  • 7. The pre-vaccination epidemiology of measles, mumps and rubella in Europe: implications for modelling studies.
    Edmunds WJ; Gay NJ; Kretzschmar M; Pebody RG; Wachmann H;
    Epidemiol Infect; 2000 Dec; 125(3):635-50. PubMed ID: 11218214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of prevaccination screening of health care workers for immunity to measles, rubella and mumps.
    Ferson MJ; Robertson PW; Whybin LR
    Med J Aust; 1994 Apr; 160(8):478-82. PubMed ID: 8170422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of surveillance of measles, mumps, and rubella in England and Wales: providing the platform for evidence-based vaccination policy.
    Vyse AJ; Gay NJ; White JM; Ramsay ME; Brown DW; Cohen BJ; Hesketh LM; Morgan-Capner P; Miller E
    Epidemiol Rev; 2002; 24(2):125-36. PubMed ID: 12762088
    [No Abstract]   [Full Text] [Related]  

  • 10. A serological survey of measles, mumps and rubella immunity among school aged children in Western Saudi Arabia.
    Jaber SM
    Saudi Med J; 2006 Jan; 27(1):63-9. PubMed ID: 16432596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination.
    Matter L; Germann D; Bally F; Schopfer K
    Eur J Epidemiol; 1997 Jan; 13(1):61-6. PubMed ID: 9062781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP).
    McLean HQ; Fiebelkorn AP; Temte JL; Wallace GS;
    MMWR Recomm Rep; 2013 Jun; 62(RR-04):1-34. PubMed ID: 23760231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic analysis of measles elimination program in the Republic of Korea, 2001: a cost benefit analysis study.
    Bae GR; Choe YJ; Go UY; Kim YI; Lee JK
    Vaccine; 2013 May; 31(24):2661-6. PubMed ID: 23602654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measles, mumps, rubella prevention: how can we do better?
    Kauffmann F; Heffernan C; Meurice F; Ota MOC; Vetter V; Casabona G
    Expert Rev Vaccines; 2021 Jul; 20(7):811-826. PubMed ID: 34096442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella.
    Tischer A; Gerike E
    Vaccine; 2000 Jan; 18(14):1382-92. PubMed ID: 10618536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The contribution of single antigen measles, mumps and rubella vaccines to immunity to these infections in England and Wales.
    Sonnenberg P; Crowcroft NS; White JM; Ramsay ME
    Arch Dis Child; 2007 Sep; 92(9):786-9. PubMed ID: 17412744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resurgence risk for measles, mumps and rubella in France in 2018 and 2020.
    Béraud G; Abrams S; Beutels P; Dervaux B; Hens N
    Euro Surveill; 2018 Jun; 23(25):. PubMed ID: 29945697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eliminating measles and rubella in Europe.
    Allerberger F
    Clin Microbiol Infect; 2017 Aug; 23(8):502-503. PubMed ID: 28412385
    [No Abstract]   [Full Text] [Related]  

  • 19. When, and how, should we introduce a combination measles-mumps-rubella (MMR) vaccine into the national childhood expanded immunization programme in South Africa?
    Cameron NA
    Vaccine; 2012 Sep; 30 Suppl 3():C58-60. PubMed ID: 22939023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection.
    Díaz Ortega JL; Castaneda D; Arellano Quintanilla DM; Martínez D; Trumbo SP; Fernández de Castro J
    Vaccine; 2017 May; 35(23):3116-3122. PubMed ID: 28457672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.